Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications.
作者信息
Uno-Eder Kiyoko
机构信息
Teikyo Academic Research Center, Teikyo University.
Department of Internal Medicine, Teikyo University School of Medicine.
出版信息
J Atheroscler Thromb. 2023 Sep 1;30(9):1106-1107. doi: 10.5551/jat.ED230. Epub 2023 Mar 22.
Abstract
摘要
相似文献
1
Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications.基于真实世界数据影响探讨亚洲使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的挑战。
J Atheroscler Thromb. 2023 Sep 1;30(9):1106-1107. doi: 10.5551/jat.ED230. Epub 2023 Mar 22.
2
Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021.2015年至2021年美国大型索赔数据库中患者获取和使用处方PCSK9抑制剂的趋势
Circ Cardiovasc Qual Outcomes. 2024 Feb;17(2):e009988. doi: 10.1161/CIRCOUTCOMES.123.009988. Epub 2024 Feb 16.
3
What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
JAAPA. 2018 Jun;31(6):14-15. doi: 10.1097/01.JAA.0000532126.38283.02.
4
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.前蛋白转化酶枯草溶菌素 9 丝氨酸蛋白酶抑制剂对原发性高胆固醇血症患者血脂水平和结局的影响：网状荟萃分析。
Eur Heart J. 2016 Feb 7;37(6):536-45. doi: 10.1093/eurheartj/ehv563. Epub 2015 Nov 17.
5
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂：在高危受试者PCSK9抑制的进一步心血管结局研究（FOURIER）试验后塑造未来。
Metabolism. 2017 Sep;74:43-46. doi: 10.1016/j.metabol.2017.04.007. Epub 2017 Apr 20.
6
Anti-PCSK9 therapies for the treatment of hypercholesterolemia.抗 PCSK9 疗法治疗高胆固醇血症。
Expert Opin Biol Ther. 2013 Mar;13(3):429-35. doi: 10.1517/14712598.2012.748743. Epub 2012 Dec 17.
7
Cost-effectiveness evaluation of the use of PCSK9 inhibitors.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂使用的成本效益评估
Endocrinol Diabetes Nutr (Engl Ed). 2021 Jun-Jul;68(6):369-371. doi: 10.1016/j.endien.2021.05.003. Epub 2021 Oct 26.
8
The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.前蛋白转化酶枯草溶菌素/kexin 9型抑制在二级预防中的新作用：从临床试验到真实世界经验
Curr Opin Cardiol. 2017 Sep;32(5):633-641. doi: 10.1097/HCO.0000000000000424.
9
Small molecules as inhibitors of PCSK9: Current status and future challenges.小分子作为 PCSK9 的抑制剂：现状和未来挑战。
Eur J Med Chem. 2019 Jan 15;162:212-233. doi: 10.1016/j.ejmech.2018.11.011. Epub 2018 Nov 11.
10
PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.用于治疗高胆固醇血症的前蛋白转化酶枯草溶菌素9（PCSK9）抑制：前景与新出现的挑战
Vascul Pharmacol. 2014 Aug;62(2):103-11. doi: 10.1016/j.vph.2014.05.011. Epub 2014 Jun 9.
引用本文的文献
1
PCSK9 inhibition: from effectiveness to cost-effectiveness.前蛋白转化酶枯草溶菌素9（PCSK9）抑制：从有效性到成本效益
Front Cardiovasc Med. 2024 Jun 25;11:1339487. doi: 10.3389/fcvm.2024.1339487. eCollection 2024.
本文引用的文献
1
Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan.在台湾，对起始使用前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂患者的治疗条件进行真实世界分析。
J Atheroscler Thromb. 2023 Sep 1;30(9):1123-1131. doi: 10.5551/jat.63789. Epub 2022 Nov 24.
2
A Comprehensive Review of PCSK9 Inhibitors.PCSK9 抑制剂的全面综述。
J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221100107. doi: 10.1177/10742484221100107.
3
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
4
Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data.美国、欧洲及其他国家前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的使用趋势：国际销售数据分析
Am Heart J. 2022 Jun;248:13-20. doi: 10.1016/j.ahj.2022.02.008. Epub 2022 Mar 1.
5
Budget impact analysis of medicines: estimated values versus real-world evidence and the implications.药品预算影响分析：估计值与真实世界证据及其影响。
Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):271-281. doi: 10.1080/14737167.2021.1927716. Epub 2021 May 27.
6
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.依洛尤单抗与急性冠脉综合征后的心血管结局。
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
7
Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.预先授权和自付费用与患者获得 PCSK9 抑制剂治疗的关联。
JAMA Cardiol. 2017 Nov 1;2(11):1217-1225. doi: 10.1001/jamacardio.2017.3451.
8
Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches.新药预算影响预测中的系统偏差：对近期美国新药上市样本的分析
Curr Med Res Opin. 2018 May;34(5):765-773. doi: 10.1080/03007995.2017.1320276. Epub 2017 May 3.
9
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
10
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.前蛋白转化酶枯草溶菌素9（PCSK9）基因的突变会导致常染色体显性遗传高胆固醇血症。
Nat Genet. 2003 Jun;34(2):154-6. doi: 10.1038/ng1161.
Zotero 插件